Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis

Table 1 Patient characteristics

	MELD 6-11 (n = 25)	MELD ≥ 17 (n = 25)	P value
Age, yr (IQR)	62 (56-69)	58 (56-66)	0.58
Male sex, n (%)	12 (48)	16 (64)	0.39
BMI (SD)	26 (6)	27 (6)	0.43
MELD score (IQR)	8 (7-10)	22 (19-24)	< 0.0001
Primary disease, n (%)			0.20
NASH	2 (8)	4 (16)
Nutritive toxic	15 (60)	9 (36)
Hepatitis B	2 (8)	2 (8)
Hepatitis C	5 (20)	4 (16)
Other	1 (4)	6 (24)
Listed for LT, n (%)	2 (8)	5 (20)	0.41
Renal replacement therapy, n (%)	0 (0)	2 (8)	0.49
Anticoagulants, n (%)	9 (36)	11 (44)	0.77
P2Y12–receptor inhibitor	1 (4)	0 (0)
ASA	5 (20)	8 (32)
LMWH	3 (12)	3 (12)
Laboratory parameters
Bilirubin, mg/dL (SD)	0.9 (0.5)	5.7 (4.4)	< 0.0001
Creatinine, mg/dL (SD)	0.8 (0.19)	1.9 (1.5)	< 0.0001
Urea, mg/dL (SD)	28.7 (9.6)	58.8 (41.6)	< 0.001
INR	1.1 (0.1)	1.7 (0.6)	< 0.0001
aPTT, s (SD)	30 (3.7)	35 (7.5)	0.047
Fibrinogen, mg/dL (SD)	275 (51)	209 (90)	0.006
Platelet count, 103/µL (SD)	145 (51)	138 (49)	0.60
Minimum, 103/µL	80	72
Maximum, 103/µL	275	274
Thrombocytopenia < 150 × 103/µL, n (%)	16 (64)	18 (72)	1.00

Data are given as means except for age which is presented as the median. Data comparisons were made with Mann Whitney U test or χ² test where applicable. BMI: Body mass index; MELD: Model for end-stage liver disease; NASH: Nonalcoholic steatohepatitis; INR: International normalized ratio; aPTT: Activated partial thromboplastin time; ASA: Acetylsalicylic acid; LMWH: Low-molecular-weight heparin; LT: Liver transplantation; IQR: Indicates interquartile range.